-
STAT+: Generics companies fought to stop the new drug pricing law. But they may end up benefiting
STAT+: Generics companies fought to stop the new drug pricing law. But they may end up benefiting WASHINGTON — Generic drugmakers lobbied hard against Democrats’ new law empowering Medicare to negotiate prescription drug prices. Giving the government such power seemed like an admission that generic medicines don’t do enough to keep costs down. Now that…
-
STAT+: Medicare details forthcoming penalties for drug price hikes
STAT+: Medicare details forthcoming penalties for drug price hikes WASHINGTON — The Biden administration on Thursday offered the first glimpse into how it’s planning to enact a new law that will penalize drugmakers for hiking their prices faster than inflation. The initial guidance documents for both physician-administered and pharmacy drugs offer details about the formulas…
-
STAT+: How one biotech investor is changing his calculus now that Medicare can negotiate drug prices
STAT+: How one biotech investor is changing his calculus now that Medicare can negotiate drug prices NEW YORK — Biotech investors don’t often publicly lay out their strategies, but an executive with a top investment firm on Tuesday offered a rare glimpse into the math he and others like him are doing after Democrats empowered…
Got any book recommendations?